BioLife Solutions (BLFS) Stock Price, News & Analysis

Company Overview

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies. In addition to its core media and instrumentation, BioLife provides technical support, training and validation services to help customers integrate its products into regulated processes and meet GMP-compliance requirements.

Headquartered in Bothell, Washington, BioLife Solutions serves a global customer base spanning academic research centers, contract development and manufacturing organizations (CDMOs) and commercial biopharmaceutical companies. The company has established distribution channels in North America, Europe and Asia to support the growing demand for standardized, clinical-grade preservation solutions. BioLife’s management team is led by President and Chief Executive Officer Warren T. Thompson, whose experience in the life sciences industry has guided strategic product development and expansion initiatives. Through continuous innovation in biopreservation technologies, BioLife Solutions aims to enable the safe and reliable delivery of next-generation cell therapies worldwide.

Key Stats

• Today's Range: $20.64 to $21.60
• 50-Day Range: $18.15 to $24.20
• 52-Week Range: $17.86 to $29.62
• Volume: 191,451 shs
• Average Volume: 400,621 shs
• Market Capitalization: $1.05 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Moderate Buy

BioLife Solutions Stock Analysis - MarketRank™

BioLife Solutions scored higher than 59% of companies evaluated by MarketBeat, and ranked 342nd out of 854 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioLife Solutions has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

BioLife Solutions has a consensus price target of $32.00, representing about 49.9% upside from its current price of $21.34.

Amount of Analyst Coverage

BioLife Solutions has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 177.78%

Earnings Growth

Earnings for BioLife Solutions are expected to grow by 177.78% in the coming year, from $0.09 to $0.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLife Solutions is -194.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLife Solutions is -194.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioLife Solutions has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.05% of the float of BioLife Solutions has been sold short.

Short Interest Ratio / Days to Cover

BioLife Solutions has a short interest ratio ("days to cover") of 10.49, which indicates bearish sentiment.

Change versus previous month

Short interest in BioLife Solutions has recently decreased by 7.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLife Solutions does not currently pay a dividend.

Dividend Growth

BioLife Solutions does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

BioLife Solutions has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioLife Solutions this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,009,000.00 in company stock.

Percentage Held by Insiders

2.20% of the stock of BioLife Solutions is held by insiders.

Percentage Held by Institutions

93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BLFS Stock Analysis - Frequently Asked Questions

How have BLFS shares performed this year?

BioLife Solutions' stock was trading at $24.18 on January 1st, 2026. Since then, BLFS stock has decreased by 11.7% and is now trading at $21.3410.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) announced its earnings results on Thursday, August, 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.31. The medical equipment provider had revenue of $25.42 million for the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions had a negative net margin of 4.50% and a positive trailing twelve-month return on equity of 1.71%.
Read the conference call transcript.

Who are BioLife Solutions' major shareholders?

Top institutional investors of BioLife Solutions include Stephens Investment Management Group LLC (1.39%), Peregrine Capital Management LLC (0.71%), Principal Financial Group Inc. (0.39%) and Conestoga Capital Advisors LLC (0.19%). Insiders that own company stock include Casdin Partners Master Fund, L, Aby J Mathew, Greef Roderick De, Michael Rice, Troy Wichterman, Todd Berard, Garrie Richardson, Karen A Foster, Sarah Aebersold, Geraint Phillips, Sean Werner, Joydeep Goswami, Marcus Schulz and Amy Duross.
View institutional ownership trends.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLife Solutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BLFS
• CIK: 834365
• Web: www.biolifesolutions.com
• Phone: (425) 402-1400
• Fax: 425-402-1433
• Employees: 440
• Year Founded: 1987

Price Target and Rating

• Average Price Target for BioLife Solutions: $32.00
• High Price Target: $34.00
• Low Price Target: $30.00
• Potential Upside/Downside: +48.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 239.51
• P/E Growth: N/A
• Net Income: -$4.59 million
• Net Margins: -4.50%
• Pretax Margin: -12.56%
• Return on Equity: 1.71%
• Return on Assets: 1.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.94
• Quick Ratio: 4.63

Sales & Book Value

• Annual Sales: $96.21 million
• Price / Sales: 10.96
• Cash Flow: $0.23 per share
• Price / Cash Flow: 92.63
• Book Value: $7.72 per share
• Price / Book: 2.79

Miscellaneous

• Outstanding Shares: 48,900,000
• Free Float: 47,824,000
• Market Cap: $1.05 billion
• Optionable: Optionable
• Beta: 1.97